RE:Interesting As a long since Dec 2018, the more attention on AGN the better. What we need is a clear timeline for getting this into US trials and more publicity. Regardless of outcome this puts AGN on the radar of Big Pharma a little more seriously and they will sniff around and see what else they have. AGN’s business model of repurposing drugs is sound – recent news is proof! While there are a couple of flags, they’re due to start Phase II human trials for IPF in Q2 and hopefully this isn’t delayed as they’ll get a bump out of it. While you’re here to take advantage of the COVID-19 news, there’s more to AGN. As COVID-19 is only going to get worse this seems to be a good spec investment, and as their news reaches more investors, the higher it goes. How high, when to sell? GL.